REGISTER
NMPA Approves Adamgammadex Sodium, Next-Gen Neuromuscular Block Reversal Agent
Adamgammadex Sodium Injection (brand name: Aomeikesong®), a Class 1 innovative drug independently developed in China, is a "targeted" neuromuscular block reversal agent with a novel mechanism. The approval was based on two Phase III randomised, double‑blind, positive‑controlled trials, which demonstrated that adamgammadex rapidly reverses rocuronium‑induced neuromuscular block with favourable overall efficacy stability and a good safety profile.

On 30 June 2026, the National Medical Products Administration (NMPA) of China officially approved Aomeikesong® (generic name: adamgammadex sodium injection; former proposed name: omegammadex sodium injection) for marketing, indicated for the reversal of neuromuscular blockade induced by rocuronium (the specific indication is subject to the package insert). The product is held by Hangzhou Aomo Pharmaceutical Co., Ltd. as the Marketing Authorisation Holder (MAH), and Aspen Pharmacare has obtained exclusive promotion rights in the Chinese mainland (excluding Hong Kong, Macao, and Taiwan).

Postoperative residual neuromuscular block (rNMB) refers to the incomplete recovery of neuromuscular function after general anaesthesia, due to incomplete metabolism of the skeletal muscle relaxant (neuromuscular blocking agent) or its metabolites. This condition can lead to upper airway obstruction, hypoxaemia, aspiration, respiratory failure, and other serious complications, even life‑threatening events. The incidence of residual neuromuscular blockade at the time of tracheal extubation after various general anaesthesia procedures is 36% (defined as train‑of‑four ratio [TOFr] < 0.9), and it reaches as high as 57% after abdominal surgery under general anaesthesia.

Over the past decades, neuromuscular reversal has evolved from an era with no available agents, to non‑"targeted" reversal with neostigmine, and then to the "targeted" reversal agent sugammadex. However, in clinical practice, safety issues such as allergic reactions, recurarisation, and laryngospasm/bronchospasm still exist. The approval of adamgammadex, a new‑generation "targeted" reversal agent, marks the official entry into a new era of "precision and safety" in neuromuscular management.

Adamgammadex is a cyclodextrin derivative that forms stable inclusion complexes with the steroidal neuromuscular blocker rocuronium, rapidly reducing the free concentration of steroidal neuromuscular blocker molecules in the blood. This shifts the dynamic equilibrium, causing the free steroidal molecules to redistribute from tissues back into the bloodstream, thereby reversing neuromuscular blockade.

In its molecular structure, adamgammadex introduces L‑acetylcysteine into the side chain, which increases the steric hindrance around the carboxyl group, enabling tighter binding to rocuronium and making dissociation less likely. This also effectively inhibits acylation with endogenous proteins, preventing the formation of immunogenic antigens and thus reducing the risk of allergic reactions by avoiding activation of the immune system.

Beyond molecular design innovations, the Aomo team has optimised the manufacturing process to achieve a single‑component, fully substituted active pharmaceutical ingredient (API). The high purity of the API helps to minimise uncertainties during drug action, providing a stronger safety margin.

As a Class 1 Chinese‑developed "targeted" neuromuscular reversal agent, this project has received continuous support from the National Major Scientific and Technological Special Project for "Significant New Drug Development" during the "Twelfth Five‑Year Plan", "Thirteenth Five‑Year Plan", and "2020" periods, fully demonstrating its innovative value.

The NMPA approval is based on the results of two Phase III clinical trials. The data show that adamgammadex rapidly reverses rocuronium‑induced neuromuscular block, with a median time to recovery of TOFr to 0.9 of 2.25 minutes after administration. In both studies, the overall safety profile of adamgammadex was favourable, with no drug‑related adverse events (allergic reactions, hypersensitivity, or laryngospasm) reported.

0
0
Loading